Organon Completes Acquisition of Forendo Pharma

Save Print

December 13, 2021 8:12 pm EDT

JERSEY CITY – Organon (NYSE: OGN) today announced the completion of its acquisition of Forendo Pharma, a clinical-stage drug development company focused on novel treatments in women’s health.

Forendo, based in Finland, is pioneering the translation of intracrinology science into first-in-class therapeutic solutions. Intracrinology enables physicians to address diseases on an unprecedented tissue-specific level. Forendo’s programs are targeting endometriosis and polycystic ovarian syndrome (PCOS).

“Organon is dedicated to delivering medically significant women’s healthcare interventions, prioritizing disease areas based on her unmet needs. Endometriosis is among our highest priority areas of focus,” said Kevin Ali, Organon’s Chief Executive Officer. “Our acquisition of Forendo further demonstrates our commitment to building a pipeline of impactful treatment options for women with unmet medical needs.”

Organon earlier announced the acquisition of Alydia Health (that focuses on postpartum hemorrhage, PPH) and the fact that Organon and ObsEva are entering an agreement whereby Organon will license the global development, manufacturing and commercial rights to a potential treatment for preterm labor.


NL-NON-110019